LIFE : Summary for aTyr Pharma, Inc. - Yahoo Finance

U.S. Markets closed

aTyr Pharma, Inc. (LIFE)


NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
3.55+0.05 (+1.43%)
At close: 4:00PM EDT
People also watch
QGENILMNPKIXRAYNWSA
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Previous Close3.50
Open3.47
Bid0.00 x
Ask3.75 x 100
Day's Range3.42 - 3.55
52 Week Range2.10 - 5.47
Volume21,391
Avg. Volume230,213
Market Cap84.31M
BetaN/A
PE Ratio (TTM)-1.45
EPS (TTM)N/A
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Associated Press8 days ago

    Atyr Pharma reports 4Q loss

    On a per-share basis, the San Diego-based company said it had a loss of 53 cents. For the year, the company reported a loss of $57.9 million, or $2.44 per share. In the final minutes of trading on Thursday, ...

  • PR Newswire10 days ago

    aTyr Pharma Announces Issuance of US Patent That Extends Patent Protection of Physiocrines Derived From 20 out of 20 Human tRNA Synthetases

    SAN DIEGO, March 15, 2017 /PRNewswire/ -- aTyr Pharma, Inc. (LIFE), a biotherapeutics company engaged in the discovery and development of Physiocrine-based therapeutics to address severe, rare diseases, today announced the issuance of US Patent Number 9,428,743, which represents the successful completion of an important aTyr milestone – the issuance of patents that cover Physiocrines derived from all 20 human tRNA synthetases. In addition, the patent portfolio covers all of aTyr's three current programs in three different therapeutic areas. "The USPTO issuance of our '743 patent represents one example of the many efforts of our scientists to meticulously explore and validate this new biology that is generating a pipeline of therapeutics based on Physiocrines," said John Mendlein, Ph.D., CEO aTyr Pharma.

  • PR Newswire22 days ago

    aTyr Pharma Receives EMA Orphan Drug Designation for the Treatment of Limb Girdle Muscular Dystrophy with Resolaris™

    SAN DIEGO, March 3, 2017 /PRNewswire/ -- aTyr Pharma, Inc. (LIFE), a biotherapeutics company engaged in the discovery and development of Physiocrine-based therapeutics to address severe, rare diseases, today announced that the European Medicines Agency (EMA) has granted orphan drug designation to Resolaris™ for the treatment of limb girdle muscular dystrophy (LGMD) patients. "As the week of International Rare Disease day concludes, we remind ourselves of our important mission to our patients – to develop new medicines based on our pioneering efforts in Physiocrine biology that we hope form the basis of meaningful changes to the lives of patients impacted by rare diseases worldwide.